MCID: FLR002
MIFTS: 56

Filariasis

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Filariasis

MalaCards integrated aliases for Filariasis:

Name: Filariasis 12 75 59 55 44 15 72 33
Disease Due to Superfamily Filarioidea 12

Characteristics:

Orphanet epidemiological data:

59
filariasis
Inheritance: Not applicable; Prevalence: >1/1000; Age of onset: All ages;

Classifications:

Orphanet: 59  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:1080
ICD9CM 35 125.9
MeSH 44 D005368
NCIt 50 C34611
SNOMED-CT 68 50342004
MESH via Orphanet 45 D005368
ICD10 via Orphanet 34 B74.0 B74.1 B74.2 more
UMLS via Orphanet 73 C0016085
Orphanet 59 ORPHA2034
UMLS 72 C0016085

Summaries for Filariasis

Disease Ontology : 12 A parasitic helminthiasis infectious disease that involves parasitic infection of the lymphatics and subcutaneous tissue by nematodes of the superfamily Filarioidea.

MalaCards based summary : Filariasis, also known as disease due to superfamily filarioidea, is related to filarial elephantiasis and onchocerciasis. An important gene associated with Filariasis is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Diethylcarbamazine and Doxycycline have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and breast, and related phenotypes are immune system and digestive/alimentary

Wikipedia : 75 Filariasis is a parasitic disease caused by an infection with roundworms of the Filarioidea type. These... more...

Related Diseases for Filariasis

Diseases related to Filariasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 507)
# Related Disease Score Top Affiliating Genes
1 filarial elephantiasis 33.8 TLR9 TLR2 IL5 IL10
2 onchocerciasis 32.7 IL5 IL2 CCL5
3 endomyocardial fibrosis 30.9 TNF IL10
4 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.8 IL10 IFNG CTLA4
5 lymphadenitis 30.7 TNF TLR4 IL10 IFNG
6 urinary schistosomiasis 30.5 IL5 IFNG CTLA4
7 ige responsiveness, atopic 30.5 IL5 IL10 IFNG
8 lymphangiosarcoma 30.4 TNF IL2 FLT4
9 leprosy 3 30.3 TNF TLR2 IL2 IL10 IFNG
10 cystic echinococcosis 30.3 TLR4 IL6 IL10
11 anterior uveitis 30.3 TLR4 IL6 CTLA4
12 poliomyelitis 30.2 TNF IL10 IFNG
13 tetanus 30.2 IL5 IL2 IL10 IFNG
14 pericarditis 30.0 TNF IL6 IFNG
15 arthritis 30.0 TNF IL6 IL10 IFNG
16 uveitis 30.0 TNF IL10 IFNG CTLA4
17 pleurisy 29.9 TNF IL2 IFNG
18 fascioliasis 29.9 IL10 IFNG ALB
19 rheumatic heart disease 29.9 TNF IL6 IL10
20 bronchitis 29.9 TNF IL5 ALB
21 chikungunya 29.9 TNF IL6 CCL5
22 schistosomiasis 29.8 TNF IL5 IL2 IL10 IFNG ALB
23 parasitic helminthiasis infectious disease 29.7 TNF TLR9 IL5 IL2 IL10
24 keratitis, hereditary 29.6 TLR9 TLR4 TLR2
25 protein-energy malnutrition 29.6 TNF IL6 ALB
26 posterior uveitis 29.6 TNF IL6 IL2 IFNG
27 endocarditis 29.5 TNF TLR2 IL6 IL10 ALB
28 immune deficiency disease 29.5 TLR9 IL2 IL10
29 end stage renal failure 29.5 TNF IL6 ALB
30 lepromatous leprosy 29.4 TNF TLR2 IL2 IL10 IFNG
31 mucocutaneous leishmaniasis 29.4 TNF TLR9 IL10
32 mastitis 29.3 TLR2 IL6 CCL5 ALB
33 yellow fever 29.3 TLR9 IL6 IL5 CCL5
34 hepatitis b 29.2 TNF IFNG CTLA4 ALB
35 rheumatic disease 29.1 TNF TLR9 IL10 IFNG
36 typhoid fever 29.1 TNF TLR4 IL6 IFNG ALB
37 lichen planus 29.1 TNF TLR9 IFNG
38 peritonitis 29.0 TNF TLR2 IL6 IL10 ALB
39 echinococcosis 29.0 TNF TLR4 TLR2 IL6 IL5 IL10
40 allergic hypersensitivity disease 29.0 TLR9 IL5 IL10 IFNG CCL5
41 chagas disease 28.9 TNF TLR4 TLR2 IL6 IL2 IL10
42 leishmaniasis 28.9 TNF TLR9 TLR4 TLR2 IL5 IL10
43 dengue hemorrhagic fever 28.9 TNF IL6 IL10 IFNG ALB
44 skin disease 28.8 TNF TLR9 IL5 IL10 IFNG
45 keratoconjunctivitis 28.6 TNF TLR9 IL5 IL2 IFNG
46 pulmonary tuberculosis 28.5 TNF TLR9 TLR2 IL2 IL10 IFNG
47 exanthem 28.5 TNF TLR9 IL6 IL2 CTLA4
48 plasmodium falciparum malaria 28.5 TNF TLR9 IL10 IFNG CHIT1
49 acquired immunodeficiency syndrome 28.5 TNF IL6 IL2 IL10 IFNG ALB
50 meningoencephalitis 28.3 TLR9 IL6 CCL5 ALB

Graphical network of the top 20 diseases related to Filariasis:



Diseases related to Filariasis

Symptoms & Phenotypes for Filariasis

MGI Mouse Phenotypes related to Filariasis:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.31 CCL5 CHIT1 CTLA4 FLT4 IFNG IL10
2 digestive/alimentary MP:0005381 10.29 ALB CTLA4 FLT4 IFNG IL10 IL2
3 hematopoietic system MP:0005397 10.29 CCL5 CTLA4 IFNG IL10 IL2 IL5
4 homeostasis/metabolism MP:0005376 10.23 ALB CTLA4 FLT4 IFNG IL10 IL2
5 cardiovascular system MP:0005385 10.18 CTLA4 FLT4 IFNG IL10 IL2 IL6
6 liver/biliary system MP:0005370 10.11 ALB CTLA4 FLT4 IFNG IL10 IL2
7 endocrine/exocrine gland MP:0005379 10.1 ALB CTLA4 IFNG IL10 IL2 IL6
8 mortality/aging MP:0010768 10.06 ALB CTLA4 FLT4 IFNG IL10 IL2
9 integument MP:0010771 10.01 CTLA4 FLT4 IFNG IL10 IL6 TLR2
10 muscle MP:0005369 9.86 ALB FLT4 IFNG IL10 IL6 TLR2
11 neoplasm MP:0002006 9.81 ALB IFNG IL10 IL2 IL5 IL6
12 reproductive system MP:0005389 9.61 FLT4 IFNG IL10 IL2 IL5 IL6
13 respiratory system MP:0005388 9.28 CTLA4 IFNG IL10 IL2 IL5 IL6

Drugs & Therapeutics for Filariasis

Drugs for Filariasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 40)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 4 90-89-1 3052
2
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
3 Lipoxygenase Inhibitors Phase 4
4 Anti-Bacterial Agents Phase 4
5 Antimalarials Phase 4
6
Petrolatum Approved, Investigational Phase 3 8009-03-8
7
Glycerol Approved, Investigational Phase 3 56-81-5 753
8 Disinfectants Phase 3
9 Sodium hypochlorite Phase 3
10 Protective Agents Phase 3
11 Eusol Phase 3
12 Vitamins Phase 3
13 Reslizumab Approved, Investigational Phase 2
14
Dihydroartemisinin Experimental, Investigational Phase 2 71939-50-9 6918483
15
Piperaquine Experimental, Investigational Phase 2 4085-31-8 5079497
16 Artemisinins Phase 2
17 Artemisinine Phase 2
18 Antibodies Phase 2
19 Respiratory System Agents Phase 2
20 Immunoglobulins Phase 2
21 Anti-Asthmatic Agents Phase 2
22 Antibodies, Monoclonal Phase 2
23 Imatinib Mesylate Phase 2 220127-57-1 123596
24 Protein Kinase Inhibitors Phase 2
25
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
26
Emodepside Investigational, Vet_approved Phase 1 155030-63-0
27 Pharmaceutical Solutions Phase 1
28
Polidocanol Approved 9002-92-0
29
Sodium citrate Approved, Investigational 68-04-2
30
Mebendazole Approved, Vet_approved 31431-39-7 4030
31
Piperazine Approved, Vet_approved 110-85-0 4837
32
Permethrin Approved, Investigational 52645-53-1 40326
33
Citric acid Approved, Nutraceutical, Vet_approved 77-92-9 311
34 Sclerosing Solutions
35 Anesthetics
36 Citrate
37 DMP 777 157341-41-8
38 Piperazine citrate
39 Liver Extracts
40 Insect Repellents

Interventional clinical trials:

(show top 50) (show all 58)
# Name Status NCT ID Phase Drugs
1 Impact of Albendazole -Ivermectin Combination Treatment on Wuchereria Bancrofti Infection and Transmission in Mali Completed NCT02784743 Phase 4 ''albendazole'' and ''ivermectin''
2 Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection: Double Blind Randomised Clinical Trial (RCT) to Study the Efficacy of Different Co-administration and Sequential Administration Completed NCT02005653 Phase 4 Diethylcarbamazine;Albendazole;Doxycycline
3 Comparison Between the Post-Treatment Reactions After Single-dose Ivermectin or DEC in Subjects With Loa Loa Infection Completed NCT01593722 Phase 4 Diethylcarbamazine;Ivermectin
4 Cluster Randomized Community-based Trial of Annual Versus Biannual Single-dose Ivermectin Plus Albendazole Against Wuchereria Bancrofti Infection in Human and Mosquito Populations Recruiting NCT03036059 Phase 4 400 μg/kg Ivermectin + 400 mg Albendazole
5 Safety of the Co-administration of Azithromycin, Albendazole and Ivermectin Versus Standard Treatment Regimens During Mass Drug Administration (MDA) in Ethiopia: a Cluster-randomized Trial Not yet recruiting NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
6 AZIVAL 2: A Double-blind Cluster-randomized Placebo-controlled Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults With Azithromycin, Ivermectin and Albendazole Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
7 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study Withdrawn NCT02734186 Phase 4 Praziquantel
8 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed NCT02509481 Phase 2, Phase 3 Ivermectin;Albendazole
9 A Randomised Controlled Trial to Evaluate the Effect of a New Skin Care Regimen on Skin Barrier Function in Those With Podoconiosis in Ethiopia Completed NCT02839772 Phase 3
10 A Cluster Randomised Trial of the Safety of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03676140 Phase 3 Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8
11 Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis Completed NCT03238131 Phase 3 Ivermectin;Albendazole
12 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) Recruiting NCT03014167 Phase 3 Albendazole
13 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02929134 Phase 3 Doxycycline;Placebo
14 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02929121 Phase 3 Doxycycline;Placebo
15 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02927496 Phase 3 Doxycycline;Placebo
16 Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa Completed NCT01975441 Phase 2 Diethylcarbamazine;Albendazole;Ivermectin
17 Effect of Albendazole and Ivermectin Dose on Wuchereria Bancrofti Microfilarial Clearance in Mali: A Randomized, Open Label Study Completed NCT00339417 Phase 2 Albendazole;Ivermectin
18 A Pharmacokinetic and Pharmacodynamic Evaluation of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03664063 Phase 2 Azithromycin;Albendazole;Ivermectin;Diethylcarbamazine
19 Effect of Albendazole Dose and Interval on Brugia Malayi Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00511004 Phase 2 Albendazole;Diethylcarbamazine
20 Effect of Albendazole Dose and Interval on Wuchereria Bancrofti Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00375583 Phase 2 DEC/Albendazole
21 Treatment of Mansonella Perstans Infection in an Area Coendemic for Lymphatic Filariasis: A Pilot Study of the Effects of Doxycycline Completed NCT00340691 Phase 2 Doxycycline
22 Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study (IVERMAL) Completed NCT02511353 Phase 2 ivermectin;placebo;dihydroartemisinin-piperaquine
23 A Randomized, Placebo-controlled, Double-Blind Pilot Study of Single-Dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa Loa Infection Completed NCT01111305 Phase 2 Reslizumab;Diethylcarbamazine
24 A Double-Blinded, Randomized, Placebo-Controlled Dose Escalation Study to Examine the Microfilaricidal Kinetics and Safety of Imatinib for the Treatment of Loa Loa (A Pilot Study) Not yet recruiting NCT02644525 Phase 2 Imatinib Mesylate;Placebo
25 A Phase 1, Single-Blind, Randomized, Placebo Controlled, Parallel-Group, Multiple-Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects Completed NCT03383614 Phase 1 LSF emodepside (BAY 44-4400) oral solution (1mg/mL)
26 A Phase 1, Blinded, Randomized, Placebo Controlled, Parallel-Group, Single-Dose, Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects Completed NCT02661178 Phase 1 emodepside (BAY 44-4400);placebo
27 Phase1,Randomized,Open-Label,Parallel-Group,Relative Bioavailability Study to Investigate PK,Including Food Effect,Safety and Tolerability of Single Doses of New Immediate Release Tablet Formulations of Emodepside (BAY 44-4400),Compared to Oral Solution,in Healthy Male Subjects Completed NCT03383523 Phase 1 Emodepside (BAY 44-4400)
28 Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Dose Treatment With Diethylcarbamazine, Albendazole and Ivermectin in Humans With and Without Wuchereria Bancrofti Infection in Côte d'Ivoire Completed NCT02845713 Phase 1 Ivermectin, Diethylcarbamazine Albendazole (IDA)
29 Lord´s Procedure Versus Sclerotherapy for Testicular Hydrocele; a Randomized Controlled Study. Unknown status NCT02082613
30 Exhaled NO Testing in Filariasis Completed NCT01628497
31 Research for Elimination of Lymphatic Filariasis (ICIDR) Completed NCT00406627
32 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India Completed NCT01629771
33 Research for Elimination of Human Filariasis Completed NCT00145223
34 A Pharmacovigilance Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults Living in the Sikasso Region of Mali Completed NCT01586169 triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
35 Studies on the Interaction Between HIV Infection, Lymphatic Filariasis and Diethylcarbamazine Completed NCT00295698 Diethylcarbamazine
36 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis Completed NCT02899936 3 drug dose - IDA;2 drug dose - DA
37 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole and diethylcarbamazine
38 Coinfection With Plasmodium Falciparum and Wuchereria Bancrofti: Clinical, Epidemiologic and Immunologic Implications Completed NCT00471666
39 Evaluation of Antibacterial Soap for Treatment of Lymphedema and Elephantiasis in an Area Endemic for Lymphatic Filariasis Completed NCT00139100 antimicrobial agent in soap
40 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
41 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Liberia Completed NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
42 Changes in HIV Viral Load in Patients Undergoing Treatment for Filarial Infection Completed NCT00344279
43 Gaps in Helminth Control: Safety and Efficacy of Drug Combinations Against Triple Infections Completed NCT01050517 albendazole + ivermectin + praziquantel;albendazole + ivermectin + (1 week later) praziquantel
44 Regulation of Innate and Adaptive Immune Responses in Individuals Infected Concurrently With Malarial and Filarial Parasites Completed NCT00341666
45 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji Completed NCT03177993 3 drug dose - IDA;3 drug dose - IDA with second dose of ivermectin;2 drug dose - DA
46 Alternative Chemotherapies for Lymphatic Filariasis (LF) Treatment and Elimination in Africa [Cote d'Ivoire] Completed NCT02974049 Albendazole;Ivermectin;Diethylcarbamazine
47 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis: Monitoring Efficacy of Ongoing Treatment Programs in Papua New Guinea Completed NCT03268252
48 Determination of the Prevalence of LF Infection in Districts Not Included in LF Control Activities and of the Basis for Integrated Implementation of LF - Onchocerciasis Elimination Strategies in Potentially Co-endemic Areas Completed NCT03131401
49 Community-Directed Treatment in the Control of Soil-Transmitted Helminths Among Children Aged 12-59 Months in Mazabuka District of Zambia Completed NCT00349323
50 Study of Patients With Known or Suspected Infection With Strongyloides Stercoralis Completed NCT00001245

Search NIH Clinical Center for Filariasis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Ivermectin
Mebendazole

Cochrane evidence based reviews: filariasis

Genetic Tests for Filariasis

Anatomical Context for Filariasis

MalaCards organs/tissues related to Filariasis:

41
Testes, Skin, Breast, T Cells, Lung, Lymph Node, Liver

Publications for Filariasis

Articles related to Filariasis:

(show top 50) (show all 6229)
# Title Authors PMID Year
1
Protective immunity in human filariasis: a role for parasite-specific IgA responses. 9 38
18588480 2008
2
Chitotriosidase deficiency is not associated with human hookworm infection in a Papua New Guinean population. 9 38
17765019 2007
3
IgE memory: persistence of antigen-specific IgE responses years after treatment of human filarial infections. 9 38
16630955 2006
4
Interleukin-10 (IL-10) counterregulates IL-4-dependent effector mechanisms in Murine Filariasis. 9 38
15501755 2004
5
Polymorphisms of innate immunity genes and susceptibility to lymphatic filariasis. 9 38
14551607 2003
6
A four year follow up study of filaria specific IgE response in individuals with hydrocele. 9 38
11247197 2000
7
IL-5 is essential for vaccine-induced protection and for resolution of primary infection in murine filariasis. 9 38
11138639 2000
8
Antigen-stimulated IL-4, IL-13 and IFN-gamma production by human T cells at a single-cell level. 9 38
9808184 1998
9
Differential decline in filaria-specific IgG1, IgG4, and IgE antibodies in Brugia malayi-infected patients after diethylcarbamazine chemotherapy. 9 38
7594718 1995
10
Differential antibody isotype reactivity to specific antigens in human lymphatic filariasis: gp15/400 preferentially induces immunoglobulin E (IgE), IgG4, and IgG2. 9 38
7558279 1995
11
Differential expression of IgE and IgG4 specific antibody responses in asymptomatic and chronic human filariasis. 9 38
8473742 1993
12
Cytokine regulation of antigen-driven immunoglobulin production in filarial parasite infections in humans. 9 38
2112154 1990
13
Evaluation of Pistia stratiotes fractions as effective larvicide against Anopheles mosquitoes. 38
30855191 2019
14
Parasitic infections in Malaysian aborigines with pulmonary tuberculosis: a comparative cross-sectional study. 38
31363922 2019
15
Rare cause of floaters: A motile live worm in vitreous cavity. 38
31436210 2019
16
Antifilarial activity of azadirachtin fuelled through reactive oxygen species induced apoptosis: a thorough molecular study on Setaria cervi. 38
30032733 2019
17
Wuchereria bancrofti infection is linked to systemic activation of CD4 and CD8 T cells. 38
31425508 2019
18
The Elimination of Neglected Tropical Diseases (NTDs): A Case Study Exemplifying How Foreign Assistance Funding Can Be Catalytic in Reducing the Burden of Major Global Health Conditions. 38
31402376 2019
19
EBM verdict: should albendazole be used for treating lymphatic filariasis? No. 38
30971416 2019
20
Development of an Antigen Detection ELISA for Bancroftian Filariasis Using BmSXP-Specific Recombinant Monoclonal Antibody. 38
31162018 2019
21
Elimination of lymphatic filariasis as a public health problem from the Arab Republic of Egypt. 38
31400299 2019
22
Correction to: How Thailand eliminated lymphatic filariasis as a public health problem. 38
31420004 2019
23
Lessons from lymphatic filariasis elimination and the challenges of post-elimination surveillance in China. 38
31387644 2019
24
Transcriptomic analysis of insecticide resistance in the lymphatic filariasis vector Culex quinquefasciatus. 38
31388075 2019
25
Progress towards lymphatic filariasis elimination in Ghana from 2000-2016: Analysis of microfilaria prevalence data from 430 communities. 38
31398203 2019
26
Immune Response to Brugia malayi Asparaginyl-tRNA Synthetase in Balb/c Mice and Human Clinical Samples of Lymphatic Filariasis. 38
30570354 2019
27
Ivermectin: From theory to clinical application. 38
31071469 2019
28
Identification and classification of differentially expressed genes in pyrethroid-resistant Culex pipiens pallens. 38
30904950 2019
29
Soil-transmitted helminth infection in school age children in Sierra Leone after a decade of preventive chemotherapy interventions. 38
31262367 2019
30
Travelers' tropical skin diseases: Challenges and interventions. 38
30216601 2019
31
Toll-like receptor polymorphism in host immune response to infectious diseases: A review. 38
31054156 2019
32
Filarial tropical pulmonary eosinophilia: a condition masquerading asthma, a series of 12 cases. 38
29969926 2019
33
Self-reactive IgG4 antibodies are associated with blocking of pathology in human lymphatic filariasis. 38
31130239 2019
34
Improved assessment of mass drug administration and health district management performance to eliminate lymphatic filariasis. 38
31276494 2019
35
Dosing pole recommendations for lymphatic filariasis elimination: A height-weight quantile regression modeling approach. 38
31314753 2019
36
Ecological and Socioeconomic Predictors of Transmission Assessment Survey Failure for Lymphatic Filariasis. 38
31115301 2019
37
The health and economic burden of lymphatic filariasis prior to mass drug administration programmes. 38
31343064 2019
38
Eliminating lymphatic filariasis - Is it worth it? 38
31343066 2019
39
Developing the first national database and map of lymphatic filariasis clinical cases in Bangladesh: Another step closer to the elimination goals. 38
31306409 2019
40
Economic performance and cost-effectiveness of using a DEC-salt social enterprise for eliminating the major neglected tropical disease, lymphatic filariasis. 38
31260444 2019
41
Potential of hydrocarbon and oxygenated monoterpenes against Culex pipiens larvae: Toxicity, biochemical, pharmacophore modeling and molecular docking studies. 38
31378352 2019
42
Production optimization and biosynthesis revision of corallopyronin A, a potent anti-filarial antibiotic. 38
31340171 2019
43
Microfilaria: not always associated with eosinophilia. 38
30895888 2019
44
Molecular Analysis of Canine Filaria and Its Wolbachia Endosymbionts in Domestic Dogs Collected from Two Animal University Hospitals in Bangkok Metropolitan Region, Thailand. 38
31362350 2019
45
New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. 38
30947125 2019
46
In Vitro And In Vivo Antifilarial Activity Of Standardized Extract Of Calotropis procera Flowers Against Brugia malayi. 38
31218959 2019
47
Troponin 1 of human filarial parasite Brugia malayi: cDNA cloning, expression, purification, and its immunoprophylactic potential. 38
31055672 2019
48
Lymphatic Filariasis. 38
31027660 2019
49
Prevalence of Neglected Tropical Diseases (Leishmaniasis and Lymphatic Filariasis) and Malaria Among a Migrant Labour Settlement in Kerala, India. 38
29860672 2019
50
Neglected Tropical Diseases: The Potential Application to Monitoring by microRNAs in the Real World. 38
31218967 2019

Variations for Filariasis

Expression for Filariasis

Search GEO for disease gene expression data for Filariasis.

Pathways for Filariasis

Pathways related to Filariasis according to GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 TNF TLR9 TLR6 TLR4 TLR2 TLR1
2
Show member pathways
13.72 TNF TLR4 IL6 IL5 IL2 IL10
3
Show member pathways
13.57 TNF IL6 IL5 IL2 IL10 IFNG
4
Show member pathways
13.45 TNF TLR9 TLR6 TLR4 TLR2 TLR1
5
Show member pathways
13.39 TNF IL6 IL5 IL2 IL10 IFNG
6
Show member pathways
13.34 TNF IL6 IL5 IL2 IL10 FLT4
7
Show member pathways
13.29 TNF TLR9 TLR6 TLR4 TLR2 TLR1
8
Show member pathways
13.04 TNF TLR4 TLR2 IL6 IL2 FLT4
9
Show member pathways
13.04 TNF TLR9 TLR6 TLR4 TLR2 TLR1
10
Show member pathways
12.97 TNF IL6 IL5 IL2 IL10 IFNG
11 12.86 IL6 IL5 IL2 IFNG FLT4
12
Show member pathways
12.8 TNF TLR4 IL6 IFNG CCL5
13
Show member pathways
12.78 TNF TLR9 TLR6 TLR4 TLR2 TLR1
14
Show member pathways
12.73 TNF TLR9 TLR6 TLR4 TLR2 TLR1
15
Show member pathways
12.7 TNF TLR4 TLR2 IL6 IL5 IL2
16
Show member pathways
12.68 TNF IL6 IL5 IL2 IL10 IFNG
17
Show member pathways
12.65 TNF IL6 IL2 IL10 IFNG
18
Show member pathways
12.52 TLR9 TLR6 TLR4 TLR2 TLR1 FLT4
19
Show member pathways
12.49 TLR6 TLR4 TLR2 TLR1
20
Show member pathways
12.48 IL6 IL5 IL2 IL10 IFNG
21
Show member pathways
12.46 TNF IL6 IL2 IFNG CCL5 ALB
22
Show member pathways
12.44 TNF TLR2 IL6 IL5 IFNG
23
Show member pathways
12.39 TNF TLR9 TLR6 TLR4 TLR2 TLR1
24
Show member pathways
12.37 TNF TLR4 TLR2 IL10 IFNG
25 12.37 TNF TLR9 TLR6 TLR2 TLR1 IL2
26
Show member pathways
12.36 TNF IL6 IL5 IL2 IL10 IFNG
27
Show member pathways
12.34 TNF TLR4 IL6 IFNG
28
Show member pathways
12.33 TNF TLR9 IL6 IL2 IL10
29
Show member pathways
12.29 TLR9 TLR6 TLR4 TLR2 TLR1 CCL5
30 12.25 TNF TLR9 TLR6 TLR4 TLR2 TLR1
31
Show member pathways
12.22 TNF TLR9 TLR6 TLR4 TLR2 TLR1
32
Show member pathways
12.18 IL6 IL5 IL2 IL10 IFNG FLT4
33 12.14 TNF TLR4 IL6 IL2 IFNG
34
Show member pathways
12.14 TNF TLR6 TLR4 TLR2 TLR1 IL6
35 12.13 TNF IL6 IL5 IL2 IL10 IFNG
36
Show member pathways
12.11 TLR9 TLR6 TLR4 TLR2 TLR1 IL5
37 12.07 TNF TLR4 TLR2 IL6 IL10 IFNG
38 11.98 TNF IL6 IL10
39 11.97 TNF IL6 CCL5
40 11.97 TNF TLR4 TLR2 IL6 IFNG CTLA4
41 11.96 TLR4 IL6 IFNG
42 11.96 IL6 IL2 IL10 IFNG
43 11.96 TLR9 TLR6 TLR4 TLR2 TLR1
44 11.93 TNF IL5 IL2 IL10 IFNG
45 11.92 IL6 IL5 IL2 IFNG
46 11.91 TNF IL6 IL5
47
Show member pathways
11.9 TNF IL5 IL2 IFNG CTLA4
48 11.89 TNF TLR9 IL6 IL2 IL10 IFNG
49 11.88 TNF TLR4 IL6 IL10
50 11.86 TNF IL6 IL2 IL10 IFNG CCL5

GO Terms for Filariasis

Cellular components related to Filariasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.8 TNF TLR6 TLR4 TLR2 TLR1 FLT4
2 membrane raft GO:0045121 9.62 TNF TLR6 TLR2 TLR1
3 extracellular space GO:0005615 9.61 TNF IL6 IL5 IL2 IL10 IFNG
4 phagocytic vesicle membrane GO:0030670 9.54 TLR6 TLR2 TLR1
5 extracellular region GO:0005576 9.36 TNF TLR9 IL6 IL5 IL2 IL10
6 Toll-like receptor 1-Toll-like receptor 2 protein complex GO:0035354 9.16 TLR2 TLR1

Biological processes related to Filariasis according to GeneCards Suite gene sharing:

(show top 50) (show all 97)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of DNA-binding transcription factor activity GO:0051091 9.96 TNF IL6 IL5 IL10
2 response to virus GO:0009615 9.95 TNF IFNG CCL5
3 cellular response to interferon-gamma GO:0071346 9.94 TLR4 TLR2 CCL5
4 defense response to Gram-positive bacterium GO:0050830 9.94 TNF TLR2 IL6
5 positive regulation of JNK cascade GO:0046330 9.94 TNF TLR9 TLR4 FLT4
6 defense response to Gram-negative bacterium GO:0050829 9.93 TLR9 TLR4 IL6
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.93 IL6 IL2 IFNG CCL5
8 response to glucocorticoid GO:0051384 9.92 TNF IL6 IL10
9 regulation of insulin secretion GO:0050796 9.92 TNF IFNG CCL5
10 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.91 TNF TLR9 TLR4
11 positive regulation of T cell proliferation GO:0042102 9.91 IL6 IL2 CCL5
12 humoral immune response GO:0006959 9.91 TNF IL6 IFNG
13 positive regulation of smooth muscle cell proliferation GO:0048661 9.9 TNF IL6 CCL5
14 positive regulation of tumor necrosis factor production GO:0032760 9.9 TLR9 TLR4 TLR2
15 positive regulation of interferon-gamma production GO:0032729 9.89 TNF TLR4 IL2
16 positive regulation of JUN kinase activity GO:0043507 9.88 TNF TLR9 TLR6
17 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.88 TNF TLR9 TLR4 TLR2
18 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.88 TNF TLR9 TLR6 TLR4 TLR2 IL6
19 positive regulation of nitric oxide biosynthetic process GO:0045429 9.86 TNF TLR6 TLR4 IFNG
20 positive regulation of B cell proliferation GO:0030890 9.85 TLR9 TLR4 IL5 IL2
21 positive regulation of inflammatory response GO:0050729 9.85 TNF TLR9 TLR4 TLR2 IL2
22 positive regulation of interferon-beta production GO:0032728 9.84 TLR9 TLR4 TLR2
23 lipopolysaccharide-mediated signaling pathway GO:0031663 9.84 TNF TLR4 TLR2 CCL5
24 positive regulation of JAK-STAT cascade GO:0046427 9.83 IL6 IL5 CCL5
25 positive regulation of interleukin-10 production GO:0032733 9.83 TLR9 TLR4 TLR2
26 positive regulation of interleukin-6 production GO:0032755 9.83 TNF TLR9 TLR4 TLR2 IL6
27 microglial cell activation GO:0001774 9.82 TNF TLR6 TLR2
28 positive regulation of macrophage activation GO:0043032 9.81 TLR6 TLR4 IL10
29 regulation of regulatory T cell differentiation GO:0045589 9.81 IL2 IFNG CTLA4
30 negative regulation of interleukin-6 production GO:0032715 9.81 TNF TLR9 TLR4 IL10
31 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.8 TLR9 TLR4 TLR2
32 positive regulation of interleukin-8 production GO:0032757 9.8 TNF TLR9 TLR4 TLR2
33 response to molecule of bacterial origin GO:0002237 9.79 TLR9 TLR2 IL10
34 positive regulation of immunoglobulin secretion GO:0051024 9.79 IL6 IL5 IL2
35 positive regulation of glial cell proliferation GO:0060252 9.78 TNF IL6
36 I-kappaB phosphorylation GO:0007252 9.78 TLR9 TLR4 TLR2
37 positive regulation of interleukin-12 production GO:0032735 9.78 TLR9 TLR4 TLR2 IFNG
38 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.77 TLR6 TLR4
39 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.77 TNF IFNG
40 negative regulation of B cell proliferation GO:0030889 9.77 IL10 CTLA4
41 positive regulation of interleukin-8 secretion GO:2000484 9.77 TLR2 TLR1
42 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.77 TNF IL10
43 negative regulation of growth of symbiont in host GO:0044130 9.77 TNF IL10
44 positive regulation of reactive oxygen species biosynthetic process GO:1903428 9.77 TLR6 TLR4
45 cell activation GO:0001775 9.77 TLR6 TLR2 TLR1
46 toll-like receptor signaling pathway GO:0002224 9.77 TLR9 TLR6 TLR4 TLR2 TLR1
47 positive regulation of podosome assembly GO:0071803 9.76 TNF IL5
48 negative regulation of interleukin-17 production GO:0032700 9.76 TLR4 IFNG
49 positive regulation of tumor necrosis factor biosynthetic process GO:0042535 9.76 TLR4 TLR1
50 macrophage activation GO:0042116 9.76 TLR4 TLR1

Molecular functions related to Filariasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.87 TNF TLR6 TLR4 TLR2 TLR1 CCL5
2 signaling receptor activity GO:0038023 9.73 TLR6 TLR4 TLR2 TLR1
3 growth factor activity GO:0008083 9.67 IL6 IL5 IL2 IL10
4 signaling pattern recognition receptor activity GO:0008329 9.46 TLR9 TLR2
5 transmembrane signaling receptor activity GO:0004888 9.46 TLR9 TLR6 TLR4 TLR1
6 lipopolysaccharide receptor activity GO:0001875 9.4 TLR4 TLR2
7 Toll-like receptor 2 binding GO:0035663 9.26 TLR6 TLR1
8 cytokine activity GO:0005125 9.17 TNF IL6 IL5 IL2 IL10 IFNG
9 lipopeptide binding GO:0071723 9.13 TLR6 TLR2 TLR1
10 protein binding GO:0005515 10.32 TNF TLR6 TLR4 TLR2 TLR1 IL6

Sources for Filariasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....